Combining Photodynamic Therapy with Immunostimulatory Nanoparticles Elicits Effective Anti-Tumor Immune Responses in Preclinical Murine Models.
immunotherapy
in situ vaccination
nanoparticles
neoepitopes
photodynamic therapy
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
14 Sep 2021
14 Sep 2021
Historique:
received:
23
07
2021
revised:
03
09
2021
accepted:
10
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Photodynamic therapy (PDT) has shown encouraging but limited clinical efficacy when used as a standalone treatment against solid tumors. Conversely, a limitation for immunotherapeutic efficacy is related to the immunosuppressive state observed in large, advanced tumors. In the present study, we employ a strategy, in which we use a combination of PDT and immunostimulatory nanoparticles (NPs), consisting of poly(lactic-co-glycolic) acid (PLGA)-polyethylene glycol (PEG) particles, loaded with the Toll-like receptor 3 (TLR3) agonist poly(I:C), the TLR7/8 agonist R848, the lymphocyte-attracting chemokine, and macrophage inflammatory protein 3α (MIP3α). The combination provoked strong anti-tumor responses, including an abscopal effects, in three clinically relevant murine models of cancer: MC38 (colorectal), CT26 (colorectal), and TC-1 (human papillomavirus 16-induced). We show that the local and distal anti-tumor effects depended on the presence of CD8
Identifiants
pubmed: 34575546
pii: pharmaceutics13091470
doi: 10.3390/pharmaceutics13091470
pmc: PMC8465537
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Nederlandse Organisatie voor Wetenschappelijk Onderzoek
ID : 723.012.110
Organisme : Leids Universitair Medisch Centrum
ID : 1234
Références
World J Gastroenterol. 2016 Jan 14;22(2):833-41
pubmed: 26811629
Nature. 2014 Nov 27;515(7528):572-6
pubmed: 25428506
J Clin Med. 2020 Jan 24;9(2):
pubmed: 31991650
Oncotarget. 2015 Jul 10;6(19):17135-46
pubmed: 25915530
Clin Cancer Res. 2016 Mar 15;22(6):1459-68
pubmed: 26546617
Cancer Biol Ther. 2010 Dec 15;10(12):1219-23
pubmed: 20930504
ACS Nano. 2020 Jan 28;14(1):620-631
pubmed: 31877023
Biomaterials. 2019 Nov;220:119417
pubmed: 31419588
PLoS One. 2014 Aug 20;9(8):e105778
pubmed: 25140900
J Control Release. 2020 Apr 10;320:19-31
pubmed: 31899272
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
J Immunol. 2006 Jul 15;177(2):1017-27
pubmed: 16818758
Adv Sci (Weinh). 2019 Sep 12;6(22):1901690
pubmed: 31763151
Nat Biotechnol. 2003 Oct;21(10):1184-91
pubmed: 14520404
Cell Death Differ. 2017 Mar;24(3):385-396
pubmed: 27834952
Br J Surg. 1990 Jan;77(1):93-6
pubmed: 2302524
Cancer Immunol Res. 2017 Oct;5(10):832-838
pubmed: 28851692
Dev Comp Immunol. 2015 Mar;49(1):113-20
pubmed: 25475963
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32873723
Cancer Immunol Res. 2014 Aug;2(8):756-64
pubmed: 24950688
Nat Commun. 2016 Aug 17;7:12499
pubmed: 27530650
J Immunol. 2010 Apr 15;184(8):4276-83
pubmed: 20304825
Front Immunol. 2018 Dec 11;9:2909
pubmed: 30619273
Mol Med Rep. 2015 Sep;12(3):3515-3520
pubmed: 26043701
J Control Release. 2016 Feb 10;223:31-41
pubmed: 26708021
Cancers (Basel). 2017 Feb 18;9(2):
pubmed: 28218708
Oncoimmunology. 2016 Sep 9;5(11):e1230578
pubmed: 27999739
Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2066-71
pubmed: 22308357
Nat Rev Cancer. 2017 May;17(5):286-301
pubmed: 28338065
Neoplasia. 2008 Nov;10(11):1183-94
pubmed: 18953427
Nat Med. 2009 Oct;15(10):1170-8
pubmed: 19767732
Cancer Res. 2005 Feb 1;65(3):1018-26
pubmed: 15705903
EMBO J. 2012 Mar 7;31(5):1062-79
pubmed: 22252128
EMBO Mol Med. 2014 Sep 17;6(10):1294-311
pubmed: 25231413
J Mater Chem B. 2020 Jul 1;8(25):5451-5459
pubmed: 32459249
Cell Death Differ. 2012 Sep;19(9):1482-94
pubmed: 22421964
Adv Healthc Mater. 2020 Jan;9(1):e1900996
pubmed: 31746153
Cancer Immunol Res. 2015 Aug;3(8):902-14
pubmed: 25898986
Curr Top Microbiol Immunol. 2002;270:169-84
pubmed: 12467251
Polymers (Basel). 2011 Sep 1;3(3):1377-1397
pubmed: 22577513
Cancer Lett. 2012 Nov 1;324(1):58-65
pubmed: 22554711
PLoS One. 2011 Jan 07;6(1):e15366
pubmed: 21249124
Cancer. 1988 Aug 15;62(4):691-701
pubmed: 2969279
Oncoimmunology. 2019 Oct 13;9(1):1673125
pubmed: 32923109
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Adv Sci (Weinh). 2020 Jul 01;7(16):2001088
pubmed: 32832363
Nat Rev Clin Oncol. 2017 Jan;14(1):57-66
pubmed: 27377132
Theranostics. 2019 Jul 29;9(19):5542-5557
pubmed: 31534502
ACS Nano. 2019 Mar 26;13(3):3083-3094
pubmed: 30835435
Mol Pharm. 2019 Jan 7;16(1):339-348
pubmed: 30452269
Immunol Rev. 2007 Dec;220:22-34
pubmed: 17979837
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Photochem Photobiol. 2019 Nov;95(6):1288-1305
pubmed: 31602649
Photochem Photobiol. 2001 Nov;74(5):712-20
pubmed: 11723800
J Biol Chem. 1997 Feb 28;272(9):5846-53
pubmed: 9038201
Theranostics. 2019 Aug 21;9(22):6485-6500
pubmed: 31588231
Biomaterials. 2016 Mar;83:308-20
pubmed: 26796043
Biomaterials. 2011 Aug;32(22):5134-47
pubmed: 21514665
Adv Mater. 2019 Dec;31(52):e1904997
pubmed: 31721331
J Immunol. 2005 Jun 15;174(12):7815-22
pubmed: 15944286
Nature. 2009 Sep 10;461(7261):282-6
pubmed: 19741708
Nat Rev Drug Discov. 2015 Aug;14(8):561-84
pubmed: 26228759
Mol Pharm. 2011 Apr 4;8(2):520-31
pubmed: 21381651
Oncoimmunology. 2018 Oct 11;7(12):e1526250
pubmed: 30524908
Methods Enzymol. 2012;509:143-63
pubmed: 22568905
Cell Death Differ. 2010 Jun;17(6):942-51
pubmed: 20019748
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Nature. 2002 Jul 11;418(6894):191-5
pubmed: 12110890
Carcinogenesis. 2008 Jul;29(7):1334-42
pubmed: 18566014
J Control Release. 2010 Jun 1;144(2):118-26
pubmed: 20156497
Nat Biomed Eng. 2018 Aug;2(8):578-588
pubmed: 31015631
Cancer Immunol Res. 2015 Jun;3(6):678-88
pubmed: 25678582
Nat Commun. 2019 Jul 26;10(1):3349
pubmed: 31350406
Biomaterials. 2021 Feb;269:120654
pubmed: 33434712
ACS Nano. 2017 May 23;11(5):4463-4474
pubmed: 28362496
Cancer Res. 1996 Jan 1;56(1):21-6
pubmed: 8548765